Growth of diabetes drug expenditure decomposed—A nationwide analysis
•Volume growth and switches to newer drugs were the main cost drivers.•Price changes had decreasing effect on the overall diabetes drug expenditure.•Different sources of expenditure increase require different actions. The aim of this study was to quantify different factors underlying the growth of d...
Saved in:
Published in | Health policy (Amsterdam) Vol. 122; no. 12; pp. 1326 - 1332 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.12.2018
Elsevier Science Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Volume growth and switches to newer drugs were the main cost drivers.•Price changes had decreasing effect on the overall diabetes drug expenditure.•Different sources of expenditure increase require different actions.
The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland.
Data representing purchases of antidiabetic agents between 2003 and 2015 were extracted from a nationwide prescription register. By using Fisher's Ideal Indexes, the per capita expenditure growth for both insulins and non-insulin antidiabetic agents was decomposed into six different determinants: purchase volume, purchase size, switches between therapeutic classes, switches within therapeutic classes, unit costs and switches to generic alternatives.
Between 2003 and 2015, the per capita expenditure on insulins increased by €8.64 and on non-insulins by €13.73. For insulins, holding other factors constant, change in the number of purchases represented a €4.67 increase in expenditure, change in the size of purchases a €4.33 increase and switches between therapeutic classes a €4.07 increase. For non-insulins, change in the number of purchases represented a €10.22 increase in expenditure and switches between therapeutic classes, a €10.17 increase. Changes in purchase size increased the non-insulin per capita expenditure by €1.48. For both insulins and non-insulins, changes in prices and product level switches had decreasing effects on expenditures.
The main drivers of the growth in diabetes drug expenditure were volume growth and switches to newer and more expensive drugs. Price changes, however, had a decreasing effect on the overall diabetes drug expenditure. |
---|---|
AbstractList | •Volume growth and switches to newer drugs were the main cost drivers.•Price changes had decreasing effect on the overall diabetes drug expenditure.•Different sources of expenditure increase require different actions.
The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland.
Data representing purchases of antidiabetic agents between 2003 and 2015 were extracted from a nationwide prescription register. By using Fisher's Ideal Indexes, the per capita expenditure growth for both insulins and non-insulin antidiabetic agents was decomposed into six different determinants: purchase volume, purchase size, switches between therapeutic classes, switches within therapeutic classes, unit costs and switches to generic alternatives.
Between 2003 and 2015, the per capita expenditure on insulins increased by €8.64 and on non-insulins by €13.73. For insulins, holding other factors constant, change in the number of purchases represented a €4.67 increase in expenditure, change in the size of purchases a €4.33 increase and switches between therapeutic classes a €4.07 increase. For non-insulins, change in the number of purchases represented a €10.22 increase in expenditure and switches between therapeutic classes, a €10.17 increase. Changes in purchase size increased the non-insulin per capita expenditure by €1.48. For both insulins and non-insulins, changes in prices and product level switches had decreasing effects on expenditures.
The main drivers of the growth in diabetes drug expenditure were volume growth and switches to newer and more expensive drugs. Price changes, however, had a decreasing effect on the overall diabetes drug expenditure. Objectives The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland. Methods Data representing purchases of antidiabetic agents between 2003 and 2015 were extracted from a nationwide prescription register. By using Fisher's Ideal Indexes, the per capita expenditure growth for both insulins and non-insulin antidiabetic agents was decomposed into six different determinants: purchase volume, purchase size, switches between therapeutic classes, switches within therapeutic classes, unit costs and switches to generic alternatives. Results Between 2003 and 2015, the per capita expenditure on insulins increased by €8.64 and on non-insulins by €13.73. For insulins, holding other factors constant, change in the number of purchases represented a €4.67 increase in expenditure, change in the size of purchases a €4.33 increase and switches between therapeutic classes a €4.07 increase. For non-insulins, change in the number of purchases represented a €10.22 increase in expenditure and switches between therapeutic classes, a €10.17 increase. Changes in purchase size increased the non-insulin per capita expenditure by €1.48. For both insulins and non-insulins, changes in prices and product level switches had decreasing effects on expenditures. Conclusions The main drivers of the growth in diabetes drug expenditure were volume growth and switches to newer and more expensive drugs. Price changes, however, had a decreasing effect on the overall diabetes drug expenditure. The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland. Data representing purchases of antidiabetic agents between 2003 and 2015 were extracted from a nationwide prescription register. By using Fisher's Ideal Indexes, the per capita expenditure growth for both insulins and non-insulin antidiabetic agents was decomposed into six different determinants: purchase volume, purchase size, switches between therapeutic classes, switches within therapeutic classes, unit costs and switches to generic alternatives. Between 2003 and 2015, the per capita expenditure on insulins increased by €8.64 and on non-insulins by €13.73. For insulins, holding other factors constant, change in the number of purchases represented a €4.67 increase in expenditure, change in the size of purchases a €4.33 increase and switches between therapeutic classes a €4.07 increase. For non-insulins, change in the number of purchases represented a €10.22 increase in expenditure and switches between therapeutic classes, a €10.17 increase. Changes in purchase size increased the non-insulin per capita expenditure by €1.48. For both insulins and non-insulins, changes in prices and product level switches had decreasing effects on expenditures. The main drivers of the growth in diabetes drug expenditure were volume growth and switches to newer and more expensive drugs. Price changes, however, had a decreasing effect on the overall diabetes drug expenditure. OBJECTIVESThe aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland.METHODSData representing purchases of antidiabetic agents between 2003 and 2015 were extracted from a nationwide prescription register. By using Fisher's Ideal Indexes, the per capita expenditure growth for both insulins and non-insulin antidiabetic agents was decomposed into six different determinants: purchase volume, purchase size, switches between therapeutic classes, switches within therapeutic classes, unit costs and switches to generic alternatives.RESULTSBetween 2003 and 2015, the per capita expenditure on insulins increased by €8.64 and on non-insulins by €13.73. For insulins, holding other factors constant, change in the number of purchases represented a €4.67 increase in expenditure, change in the size of purchases a €4.33 increase and switches between therapeutic classes a €4.07 increase. For non-insulins, change in the number of purchases represented a €10.22 increase in expenditure and switches between therapeutic classes, a €10.17 increase. Changes in purchase size increased the non-insulin per capita expenditure by €1.48. For both insulins and non-insulins, changes in prices and product level switches had decreasing effects on expenditures.CONCLUSIONSThe main drivers of the growth in diabetes drug expenditure were volume growth and switches to newer and more expensive drugs. Price changes, however, had a decreasing effect on the overall diabetes drug expenditure. |
Author | Saastamoinen, Leena Soppi, Aarni Aaltonen, Katri Kurko, Terhi Heino, Pekka Maljanen, Timo |
Author_xml | – sequence: 1 givenname: Aarni orcidid: 0000-0001-9890-1381 surname: Soppi fullname: Soppi, Aarni email: aarni.soppi@kela.fi – sequence: 2 givenname: Pekka surname: Heino fullname: Heino, Pekka – sequence: 3 givenname: Terhi surname: Kurko fullname: Kurko, Terhi – sequence: 4 givenname: Timo surname: Maljanen fullname: Maljanen, Timo – sequence: 5 givenname: Leena surname: Saastamoinen fullname: Saastamoinen, Leena – sequence: 6 givenname: Katri surname: Aaltonen fullname: Aaltonen, Katri |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30297302$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkLtOwzAUhi0EoqXwChCJhSXBTlI7HquKm4TEArPl2CfUVRoH2-Gy8RA8IU-Cq5YOLCznLN9_Lt8R2u9sBwidEZwRTOjlMluAbMOit22WY1JlmGcYV3toTCqWpxRPy300jmSVVlOCR-jI-yXGmBUFPUSjAuecxTJG1zfOvoVFYptEG1lDAJ9oNzwn8N5Dp00YHCQalF311oP-_vyaJZ0MxnZvRkMiO9l-eOOP0UEjWw8n2z5BT9dXj_Pb9P7h5m4-u09VwXlIa8I5laBlyWpZgtR5U6q8IqRsWNEwxRTHkvKClFWNdcN5BJSuNDAFueZ1MUEXm7m9sy8D-CBWxitoW9mBHbzICWEFz2n8c4LO_6BLO7h475pinDJC6TRSbEMpZ7130IjemZV0H4JgsVYtlmKnWqxVC8xFVB2Tp9v5Q70Cvcv9uo3AbANAFPJqwAmvDHQKtHGggtDW_LvkBzL4l3Y |
CitedBy_id | crossref_primary_10_1002_art_41138 crossref_primary_10_1016_j_ajic_2024_01_012 crossref_primary_10_1215_03616878_10041149 crossref_primary_10_3389_fphar_2021_681492 crossref_primary_10_1016_j_healthpol_2021_05_007 crossref_primary_10_1371_journal_pone_0250305 crossref_primary_10_3390_jcdd7010006 crossref_primary_10_1007_s40200_024_01444_0 crossref_primary_10_3399_bjgp20X714089 crossref_primary_10_1016_j_hlpt_2020_02_007 crossref_primary_10_1186_s12939_022_01631_6 crossref_primary_10_1016_j_glohj_2019_11_001 crossref_primary_10_1111_1753_0407_13491 |
Cites_doi | 10.1097/01.mlr.0000129494.36245.4b 10.3109/07853890.2016.1146825 10.1016/j.vhri.2013.01.002 10.2147/CLEP.S113211 10.1056/NEJMms1411398 10.3349/ymj.2016.57.4.1016 10.1016/j.vhri.2015.01.004 10.2165/00019053-200422010-00003 10.2337/dc13-2289 10.1111/1475-6773.01058 10.1016/j.clinthera.2009.07.003 |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. Dec 2018 |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. Dec 2018 |
DBID | NPM AAYXX CITATION 7QJ 7TQ 8BJ DHY DON FQK JBE 7X8 |
DOI | 10.1016/j.healthpol.2018.09.008 |
DatabaseName | PubMed CrossRef Applied Social Sciences Index & Abstracts (ASSIA) PAIS Index International Bibliography of the Social Sciences (IBSS) PAIS International PAIS International (Ovid) International Bibliography of the Social Sciences International Bibliography of the Social Sciences MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef International Bibliography of the Social Sciences (IBSS) Applied Social Sciences Index and Abstracts (ASSIA) PAIS International MEDLINE - Academic |
DatabaseTitleList | International Bibliography of the Social Sciences (IBSS) PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1872-6054 |
EndPage | 1332 |
ExternalDocumentID | 10_1016_j_healthpol_2018_09_008 30297302 S0168851018304913 |
Genre | Journal Article |
GroupedDBID | --- --K --M ..I .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAWTL AAXUO ABBQC ABFNM ABIVO ABJNI ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACGFS ACHQT ACIUM ACRLP ADBBV ADEZE AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEH HMK HMO HVGLF HZ~ IHE J1W KOM LCYCR M29 M3W M41 MO0 MS~ N9A O-L O9- OAUVE OHT OZT P-8 P-9 P2P PC. PQQKQ Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TN5 UHS WUQ Z5R ZGI ~G- AAXKI ADMHG AFJKZ AKRWK NPM AAYXX CITATION 7QJ 7TQ 8BJ DHY DON FQK JBE 7X8 |
ID | FETCH-LOGICAL-c399t-b1996aeda47ba4ead2f4c28114f73f7c7c90a693148b0df99d2fcd8de7ce2d9b3 |
IEDL.DBID | AIKHN |
ISSN | 0168-8510 |
IngestDate | Fri Oct 25 23:18:06 EDT 2024 Thu Oct 10 22:32:33 EDT 2024 Thu Nov 21 20:26:32 EST 2024 Wed Oct 16 00:49:47 EDT 2024 Fri Feb 23 02:25:08 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Diabetes drugs Growth Fisher’s ideal index Drug expenditures |
Language | English |
License | Copyright © 2018 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c399t-b1996aeda47ba4ead2f4c28114f73f7c7c90a693148b0df99d2fcd8de7ce2d9b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-9890-1381 |
PMID | 30297302 |
PQID | 2179671665 |
PQPubID | 105626 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2117392673 proquest_journals_2179671665 crossref_primary_10_1016_j_healthpol_2018_09_008 pubmed_primary_30297302 elsevier_sciencedirect_doi_10_1016_j_healthpol_2018_09_008 |
PublicationCentury | 2000 |
PublicationDate | December 2018 2018-Dec 2018-12-00 20181201 |
PublicationDateYYYYMMDD | 2018-12-01 |
PublicationDate_xml | – month: 12 year: 2018 text: December 2018 |
PublicationDecade | 2010 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland – name: Amsterdam |
PublicationTitle | Health policy (Amsterdam) |
PublicationTitleAlternate | Health Policy |
PublicationYear | 2018 |
Publisher | Elsevier B.V Elsevier Science Ltd |
Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd |
References | Jacobzone (bib0070) 2000 WHO Collaborating Centre for Drug Statistics Methodology (bib0150) 2015 Greene, Riggs (bib0200) 2015; 372 Morgan (bib0105) 2004; 42 Government Proposal 622/2012. Socialstyrelsen (bib0050) National Institute for Health and Welfare (bib0120) 2017 Morgan (bib0100) 2002; 37 The Wolrd Bank (bib0015) Fisher (bib0160) 1922 OECD (bib0005) 2015 Wu, Yue, Xu (bib0110) 2013; 2 Christensen, Rungby, Thomsen (bib0175) 2016; 8 (bib0205) 2016 (Accessed January 31, 2017). Gerdtham, Lundin (bib0080) 2004; 22 Sund, Koski (bib0170) 2009 Government Proposal 97/2005. National Agency for Medicines, Social Insurance Institution (bib0025) 2016 Merlis (bib0075) 2000 Kwon, Yang, Godman (bib0095) 2015; 6 Health Insurance Act 1224/2004. R Development, Core Team (bib0165) 2018 Government Proposal 100/2008. Fimea Drug consumption in years 2013-2015. Government Proposal 165/2002. Ruskoaho (bib0035) 2016 Finnish Diabetes Association (bib0190) 2001 Diewert, Nakamura (bib0155) 1993; vol. 1 Kanavos, Vandoros, Nicod (bib0060) 2011 Hampp, Borders-Hemphill, Moeny, Wysowski (bib0180) 2014; 37 Aaltonen, Saastamoinen (bib0055) 2013 Folkhelseinstituttet (bib0040) Pharma Industry Finland (bib0030) 2016 Koskinen, Martikainen, Maljanen (bib0090) 2009; 31 Government Proposal 330/2014. Jo, Kim, Paek, Bea, Chun, Lee (bib0085) 2016; 57 Sundetsdata-styrelsen (bib0045) Järvinen, Laine, Eriksson (bib0185) 2016; 48 National Agency for Medicines, Social Insurance Institution (bib0020) 2004 International Diabetes Federation (bib0010) 2015 Fimea Drug sales in years 2013-2015 Seiter (bib0065) 2010 The Pharmaceuticals Pricing Board (bib0195) 2015 Finnish Diabetes Association (10.1016/j.healthpol.2018.09.008_bib0190) 2001 Aaltonen (10.1016/j.healthpol.2018.09.008_bib0055) 2013 Kwon (10.1016/j.healthpol.2018.09.008_bib0095) 2015; 6 Sundetsdata-styrelsen (10.1016/j.healthpol.2018.09.008_bib0045) Morgan (10.1016/j.healthpol.2018.09.008_bib0100) 2002; 37 Ruskoaho (10.1016/j.healthpol.2018.09.008_bib0035) 2016 Folkhelseinstituttet (10.1016/j.healthpol.2018.09.008_bib0040) Merlis (10.1016/j.healthpol.2018.09.008_bib0075) 2000 Fisher (10.1016/j.healthpol.2018.09.008_bib0160) 1922 National Institute for Health and Welfare (10.1016/j.healthpol.2018.09.008_bib0120) 2017 10.1016/j.healthpol.2018.09.008_bib0130 10.1016/j.healthpol.2018.09.008_bib0135 Hampp (10.1016/j.healthpol.2018.09.008_bib0180) 2014; 37 10.1016/j.healthpol.2018.09.008_bib0210 National Agency for Medicines, Social Insurance Institution (10.1016/j.healthpol.2018.09.008_bib0025) 2016 (10.1016/j.healthpol.2018.09.008_bib0205) 2016 Gerdtham (10.1016/j.healthpol.2018.09.008_bib0080) 2004; 22 Jacobzone (10.1016/j.healthpol.2018.09.008_bib0070) 2000 The Wolrd Bank (10.1016/j.healthpol.2018.09.008_bib0015) Morgan (10.1016/j.healthpol.2018.09.008_bib0105) 2004; 42 R Development (10.1016/j.healthpol.2018.09.008_bib0165) 2018 OECD (10.1016/j.healthpol.2018.09.008_bib0005) 2015 Järvinen (10.1016/j.healthpol.2018.09.008_bib0185) 2016; 48 WHO Collaborating Centre for Drug Statistics Methodology (10.1016/j.healthpol.2018.09.008_bib0150) 2015 International Diabetes Federation (10.1016/j.healthpol.2018.09.008_bib0010) 2015 Seiter (10.1016/j.healthpol.2018.09.008_bib0065) 2010 Jo (10.1016/j.healthpol.2018.09.008_bib0085) 2016; 57 Sund (10.1016/j.healthpol.2018.09.008_bib0170) 2009 10.1016/j.healthpol.2018.09.008_bib0140 10.1016/j.healthpol.2018.09.008_bib0125 Pharma Industry Finland (10.1016/j.healthpol.2018.09.008_bib0030) 2016 10.1016/j.healthpol.2018.09.008_bib0145 Diewert (10.1016/j.healthpol.2018.09.008_bib0155) 1993; vol. 1 Kanavos (10.1016/j.healthpol.2018.09.008_bib0060) 2011 Greene (10.1016/j.healthpol.2018.09.008_bib0200) 2015; 372 10.1016/j.healthpol.2018.09.008_bib0215 Socialstyrelsen (10.1016/j.healthpol.2018.09.008_bib0050) 10.1016/j.healthpol.2018.09.008_bib0115 Christensen (10.1016/j.healthpol.2018.09.008_bib0175) 2016; 8 Koskinen (10.1016/j.healthpol.2018.09.008_bib0090) 2009; 31 Wu (10.1016/j.healthpol.2018.09.008_bib0110) 2013; 2 National Agency for Medicines, Social Insurance Institution (10.1016/j.healthpol.2018.09.008_bib0020) 2004 The Pharmaceuticals Pricing Board (10.1016/j.healthpol.2018.09.008_bib0195) 2015 |
References_xml | – year: 2009 ident: bib0170 article-title: FinnDM II: Diabeteksen ja sen lisäsairauksien esiintyvyyden ja ilmaantuvuuden rekisteriperusteinen mittaaminen - Tekninen raportti contributor: fullname: Koski – year: 2018 ident: bib0165 article-title: R: a language and environment for statistical computing contributor: fullname: Core Team – volume: 37 start-page: 1243 year: 2002 end-page: 1266 ident: bib0100 article-title: Quantifying components of drug expenditure inflation: the British Columbia seniors’ drug benefit plan: quantifying drug expenditure inflation publication-title: Health Services Research contributor: fullname: Morgan – ident: bib0040 article-title: Norwegian prescription database contributor: fullname: Folkhelseinstituttet – year: 2016 ident: bib0035 article-title: Lääkekorvausten tarkastelua lääkkeiden näkökulmasta vuoden 2017 lääkesäästöihin liittyen. Selvitysmiehen raportti contributor: fullname: Ruskoaho – volume: 372 start-page: 1171 year: 2015 end-page: 1175 ident: bib0200 article-title: Why Is There No Generic Insulin? Historical Origins of a Modern Problem publication-title: The New England Journal of Medicine contributor: fullname: Riggs – volume: 2 start-page: 37 year: 2013 end-page: 42 ident: bib0110 article-title: Increasing anti-infective drug expenditure in Tianjin, China: a decomposition analysis publication-title: Value Health Regional Issues contributor: fullname: Xu – year: 2000 ident: bib0075 article-title: Explaining the growth in prescription drug spending: a review of recent studies contributor: fullname: Merlis – year: 1922 ident: bib0160 article-title: The making of index numbers; a study of their varieties, tests, and reliability contributor: fullname: Fisher – year: 2013 ident: bib0055 article-title: Pitkävaikutteisten insuliinianalogien ja gliptiinien käyttö yleistyy diabeteksen hoidossa contributor: fullname: Saastamoinen – year: 2016 ident: bib0025 article-title: Finnish statistics on medicines 2015 contributor: fullname: National Agency for Medicines, Social Insurance Institution – year: 2000 ident: bib0070 article-title: Pharmaceutical policies in OECD countries. Reconciling social and industrial goals contributor: fullname: Jacobzone – year: 2004 ident: bib0020 article-title: Finnish statistics on medicines 2003 contributor: fullname: National Agency for Medicines, Social Insurance Institution – volume: 57 start-page: 1016 year: 2016 end-page: 1021 ident: bib0085 article-title: Factors contributing to increases in prescription drug expenditures borne by national health insurance in South Korea publication-title: Yonsei Medical Journal contributor: fullname: Lee – volume: 6 start-page: 14 year: 2015 end-page: 21 ident: bib0095 article-title: Key components of increased drug expenditure in South Korea: implications for the future publication-title: Value Health Regional Issues contributor: fullname: Godman – volume: vol. 1 year: 1993 ident: bib0155 publication-title: Essays in index number theory contributor: fullname: Nakamura – year: 2017 ident: bib0120 article-title: Terveydenhuollon menot ja rahoitus 2015. Hälso- och sjukvårdsutgifter samt deras finansiering 2015 contributor: fullname: National Institute for Health and Welfare – year: 2016 ident: bib0030 article-title: Suhdannekatsaus contributor: fullname: Pharma Industry Finland – volume: 37 start-page: 1367 year: 2014 end-page: 1374 ident: bib0180 article-title: Use of antidiabetic drugs in the U.S., 2003-2012 publication-title: Diabetes Care contributor: fullname: Wysowski – year: 2015 ident: bib0010 article-title: IDF diabetes atlas 7th edition contributor: fullname: International Diabetes Federation – year: 2016 ident: bib0205 article-title: Working group set up by the Finnish Medical Society Duodecim, Medical Society of the Finnish diabetes Association. Current Care Guidelines – ident: bib0050 article-title: Statistikdatabas för läkemedel contributor: fullname: Socialstyrelsen – year: 2015 ident: bib0150 article-title: WHOCC contributor: fullname: WHO Collaborating Centre for Drug Statistics Methodology – volume: 42 start-page: 635 year: 2004 end-page: 642 ident: bib0105 article-title: Drug spending in Canada: recent trends and causes publication-title: Medical Care contributor: fullname: Morgan – year: 2015 ident: bib0195 article-title: Liite: Lääkkeiden hintalautakunnan päätökseen DNRO 649/5/2015 contributor: fullname: The Pharmaceuticals Pricing Board – ident: bib0045 article-title: Sundhedsdatastyrelsen – Statistikker contributor: fullname: Sundetsdata-styrelsen – volume: 48 start-page: 162 year: 2016 end-page: 168 ident: bib0185 article-title: Comparison of use of diabetic medication and clinical guidelines in four Nordic countries publication-title: Annals of Medicine contributor: fullname: Eriksson – volume: 22 start-page: 29 year: 2004 end-page: 42 ident: bib0080 article-title: Why did drug spending increase during the 1990s? A decomposition based on Swedish data publication-title: PharmacoEconomics contributor: fullname: Lundin – volume: 8 start-page: 381 year: 2016 end-page: 387 ident: bib0175 article-title: Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014 publication-title: Clinical Epidemiology contributor: fullname: Thomsen – year: 2001 ident: bib0190 article-title: Development programme for the prevention and care of diabetes in Finland 2000-2010 contributor: fullname: Finnish Diabetes Association – year: 2015 ident: bib0005 article-title: Health at a glance 2015 contributor: fullname: OECD – ident: bib0015 article-title: Diabetes prevalence (% of population ages 20 to 79) Data contributor: fullname: The Wolrd Bank – year: 2011 ident: bib0060 article-title: Differences in costs of and access to pharmaceutical products in the EU contributor: fullname: Nicod – year: 2010 ident: bib0065 article-title: A practical approach to pharmaceutical policy contributor: fullname: Seiter – volume: 31 start-page: 1469 year: 2009 end-page: 1477 ident: bib0090 article-title: Antipsychotics and antidepressants: An analysis of cost growth in finland from 1999 to 2005 publication-title: Clinical Therapeutics contributor: fullname: Maljanen – year: 2010 ident: 10.1016/j.healthpol.2018.09.008_bib0065 contributor: fullname: Seiter – volume: vol. 1 year: 1993 ident: 10.1016/j.healthpol.2018.09.008_bib0155 contributor: fullname: Diewert – volume: 42 start-page: 635 year: 2004 ident: 10.1016/j.healthpol.2018.09.008_bib0105 article-title: Drug spending in Canada: recent trends and causes publication-title: Medical Care doi: 10.1097/01.mlr.0000129494.36245.4b contributor: fullname: Morgan – year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0205 – year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0030 contributor: fullname: Pharma Industry Finland – ident: 10.1016/j.healthpol.2018.09.008_bib0135 – volume: 48 start-page: 162 year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0185 article-title: Comparison of use of diabetic medication and clinical guidelines in four Nordic countries publication-title: Annals of Medicine doi: 10.3109/07853890.2016.1146825 contributor: fullname: Järvinen – year: 2017 ident: 10.1016/j.healthpol.2018.09.008_bib0120 contributor: fullname: National Institute for Health and Welfare – ident: 10.1016/j.healthpol.2018.09.008_bib0050 contributor: fullname: Socialstyrelsen – year: 2015 ident: 10.1016/j.healthpol.2018.09.008_bib0005 contributor: fullname: OECD – volume: 2 start-page: 37 year: 2013 ident: 10.1016/j.healthpol.2018.09.008_bib0110 article-title: Increasing anti-infective drug expenditure in Tianjin, China: a decomposition analysis publication-title: Value Health Regional Issues doi: 10.1016/j.vhri.2013.01.002 contributor: fullname: Wu – year: 2018 ident: 10.1016/j.healthpol.2018.09.008_bib0165 contributor: fullname: R Development – ident: 10.1016/j.healthpol.2018.09.008_bib0125 – volume: 8 start-page: 381 year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0175 article-title: Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014 publication-title: Clinical Epidemiology doi: 10.2147/CLEP.S113211 contributor: fullname: Christensen – year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0035 contributor: fullname: Ruskoaho – ident: 10.1016/j.healthpol.2018.09.008_bib0215 – volume: 372 start-page: 1171 year: 2015 ident: 10.1016/j.healthpol.2018.09.008_bib0200 article-title: Why Is There No Generic Insulin? Historical Origins of a Modern Problem publication-title: The New England Journal of Medicine doi: 10.1056/NEJMms1411398 contributor: fullname: Greene – year: 2015 ident: 10.1016/j.healthpol.2018.09.008_bib0150 contributor: fullname: WHO Collaborating Centre for Drug Statistics Methodology – ident: 10.1016/j.healthpol.2018.09.008_bib0140 – year: 2011 ident: 10.1016/j.healthpol.2018.09.008_bib0060 contributor: fullname: Kanavos – year: 2001 ident: 10.1016/j.healthpol.2018.09.008_bib0190 contributor: fullname: Finnish Diabetes Association – volume: 57 start-page: 1016 year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0085 article-title: Factors contributing to increases in prescription drug expenditures borne by national health insurance in South Korea publication-title: Yonsei Medical Journal doi: 10.3349/ymj.2016.57.4.1016 contributor: fullname: Jo – year: 2013 ident: 10.1016/j.healthpol.2018.09.008_bib0055 contributor: fullname: Aaltonen – volume: 6 start-page: 14 year: 2015 ident: 10.1016/j.healthpol.2018.09.008_bib0095 article-title: Key components of increased drug expenditure in South Korea: implications for the future publication-title: Value Health Regional Issues doi: 10.1016/j.vhri.2015.01.004 contributor: fullname: Kwon – year: 2000 ident: 10.1016/j.healthpol.2018.09.008_bib0075 contributor: fullname: Merlis – volume: 22 start-page: 29 year: 2004 ident: 10.1016/j.healthpol.2018.09.008_bib0080 article-title: Why did drug spending increase during the 1990s? A decomposition based on Swedish data publication-title: PharmacoEconomics doi: 10.2165/00019053-200422010-00003 contributor: fullname: Gerdtham – volume: 37 start-page: 1367 year: 2014 ident: 10.1016/j.healthpol.2018.09.008_bib0180 article-title: Use of antidiabetic drugs in the U.S., 2003-2012 publication-title: Diabetes Care doi: 10.2337/dc13-2289 contributor: fullname: Hampp – year: 2004 ident: 10.1016/j.healthpol.2018.09.008_bib0020 contributor: fullname: National Agency for Medicines, Social Insurance Institution – ident: 10.1016/j.healthpol.2018.09.008_bib0040 contributor: fullname: Folkhelseinstituttet – year: 2015 ident: 10.1016/j.healthpol.2018.09.008_bib0010 contributor: fullname: International Diabetes Federation – year: 2016 ident: 10.1016/j.healthpol.2018.09.008_bib0025 contributor: fullname: National Agency for Medicines, Social Insurance Institution – ident: 10.1016/j.healthpol.2018.09.008_bib0115 – ident: 10.1016/j.healthpol.2018.09.008_bib0130 – ident: 10.1016/j.healthpol.2018.09.008_bib0210 – year: 1922 ident: 10.1016/j.healthpol.2018.09.008_bib0160 contributor: fullname: Fisher – year: 2015 ident: 10.1016/j.healthpol.2018.09.008_bib0195 contributor: fullname: The Pharmaceuticals Pricing Board – ident: 10.1016/j.healthpol.2018.09.008_bib0015 contributor: fullname: The Wolrd Bank – volume: 37 start-page: 1243 year: 2002 ident: 10.1016/j.healthpol.2018.09.008_bib0100 article-title: Quantifying components of drug expenditure inflation: the British Columbia seniors’ drug benefit plan: quantifying drug expenditure inflation publication-title: Health Services Research doi: 10.1111/1475-6773.01058 contributor: fullname: Morgan – ident: 10.1016/j.healthpol.2018.09.008_bib0145 – year: 2000 ident: 10.1016/j.healthpol.2018.09.008_bib0070 contributor: fullname: Jacobzone – volume: 31 start-page: 1469 year: 2009 ident: 10.1016/j.healthpol.2018.09.008_bib0090 article-title: Antipsychotics and antidepressants: An analysis of cost growth in finland from 1999 to 2005 publication-title: Clinical Therapeutics doi: 10.1016/j.clinthera.2009.07.003 contributor: fullname: Koskinen – ident: 10.1016/j.healthpol.2018.09.008_bib0045 contributor: fullname: Sundetsdata-styrelsen – year: 2009 ident: 10.1016/j.healthpol.2018.09.008_bib0170 contributor: fullname: Sund |
SSID | ssj0007336 |
Score | 2.3412588 |
Snippet | •Volume growth and switches to newer drugs were the main cost drivers.•Price changes had decreasing effect on the overall diabetes drug expenditure.•Different... The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland. Data representing purchases of... Objectives The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland. Methods Data representing... OBJECTIVESThe aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland.METHODSData representing... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1326 |
SubjectTerms | Antidiabetics Change agents Data analysis Diabetes Diabetes drugs Drug expenditures Drugs Expenditures Fisher’s ideal index Generic prescribing Growth Health administration Indexes Insulin Per capita Prices Purchasing |
Title | Growth of diabetes drug expenditure decomposed—A nationwide analysis |
URI | https://dx.doi.org/10.1016/j.healthpol.2018.09.008 https://www.ncbi.nlm.nih.gov/pubmed/30297302 https://www.proquest.com/docview/2179671665 https://search.proquest.com/docview/2117392673 |
Volume | 122 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6V9oKEUMsztFRG4rrEiXe9dm9R1TQF0QtUys3y-gHhsBulibhV_RH8Qn4JM-vdSJFAHHpcry1ZM_Y8PDPfALyn5uXcBZkpK1yW-1hlKgadKccDqtMonKTa4c_XcnaTf5wX8z0472thKK2yk_1JprfSuhsZdtQcLheL4Rc0VpRqEacoVESdaw9QHVGs9mBy9Wl2vRXIhPiXIL5VRgt20rxSueGyoTDESLWYp9Rq8u9K6l9GaKuMpofwtLMi2SRt9Aj2Qv0MnqQnOJYqi57D9BJd7PV31kTWv7Ayv9p8Y4TqT5HqzSowHyipvLkN_vf9rwlLb4M_Fz4w28GVvICb6cXX81nWtU3IHFob66yixGIbvM3LyuZ4UsYxd2OFjk8sRSxd6TS3Ugt0hCruo9Y4wXnlQ-nC2OtKvIT9uqnDa2BV4Z0uIvdBxlyoqIoKFZrlVlgZrR0NgPd0MsuEjmH6tLEfZktaQ6Q1XBsk7QDOenqaHUYblOH_X3zSc8B0d-3WoFOlJbp9shjAu-1vvCUU-rB1aDY0Z1SiJShLMYBXiXPbDYu2fxcfv3nIzo7hMX2lRJcT2F-vNuEtmivr6hQefbgbnXaH8g-UcuzE |
link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB5V5VAkhGgpNNCHkXpd4sS7XptbVTVNS9sLrdSb5fUD0kM2ShNxQ_wIfiG_hJn1bqpKIA69rr2SNbbn4fnmG4BDal7OXZCZssJluY9VpmLQmXI8oDmNwkmqHb68kuOb_Py2uF2D464WhmCVre5POr3R1u2XfivN_mwy6X9BZ0WphnGKUkXUufZZXqD3i4f6448HnAfx_SWCb5XR9Ecgr1RsOKspCTFQDeMpNZr8u4n6lwvamKLRK3jZ-pDsKC1zE9bCdAtepAc4luqKXsPoFAPsxTdWR9a9rzI_X35lxOlPeerlPDAfCFJe3wf_--evI5ZeBr9PfGC2JSvZhpvRyfXxOGubJmQOfY1FVhGs2AZv87KyOZ6TYczdUGHYE0sRS1c6za3UAsOgivuoNU5wXvlQujD0uhJvYH1aT8MOsKrwTheR-yBjLlRURYXmzHIrrIzWDnrAOzmZWeLGMB1o7M6sRGtItIZrg6LtwadOnubRNhvU4P__ebfbAdPetHuDIZWWGPTJogcfVsN4RyjxYaehXtKcQYl-oCxFD96mnVstWDTdu_jw3VNWdgAb4-vLC3NxdvX5PTynkQR52YX1xXwZ9tBxWVT7zcH8A72b7Z0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Growth+of+diabetes+drug+expenditure+decomposed%E2%80%94A+nationwide+analysis&rft.jtitle=Health+policy+%28Amsterdam%29&rft.au=Soppi%2C+Aarni&rft.au=Heino%2C+Pekka&rft.au=Kurko%2C+Terhi&rft.au=Maljanen%2C+Timo&rft.date=2018-12-01&rft.pub=Elsevier+B.V&rft.issn=0168-8510&rft.eissn=1872-6054&rft.volume=122&rft.issue=12&rft.spage=1326&rft.epage=1332&rft_id=info:doi/10.1016%2Fj.healthpol.2018.09.008&rft.externalDocID=S0168851018304913 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8510&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8510&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8510&client=summon |